Trial Profile

Efficacy of Peptide Receptor Radionuclide Therapy for Metastatic Inoperable Neuroendocrine Tumours Using 177-Lu-DOTA 0, Tyr 3 Octreotate

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 03 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lutetium-(177Lu)-oxodotreotide (Primary)
Indications Gastrointestinal cancer; Neuroendocrine tumours
Focus Therapeutic Use

Most Recent Events

12 Nov 2019 Status changed from recruiting to completed.
07 Oct 2016 Planned End Date changed from 1 Nov 2017 to 1 Oct 2019.
07 Oct 2016 Planned primary completion date changed from 1 Oct 2017 to 1 Oct 2019.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com